Multiple endocrine neoplasia type 2

Orphanet Journal of Rare Diseases

Volumn 1, Issue 1, 2006, Pages

  Marini, Francesca ^a   Falchetti, Alberto ^a   Del Monte, Francesca ^a   Carbonell Sala, Silvia ^a   Tognarini, Isabella ^a   Luzi, Ettore ^a   Brandi, Maria Luisa ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN RET; MEN1 PROTEIN, HUMAN; ONCOPROTEIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HUMAN; MEDULLARY CARCINOMA; MUTATION; PATHOLOGY; PHEOCHROMOCYTOMA; REVIEW; SIPPLE SYNDROME; THYROID TUMOR; ADOLESCENT; ADRENAL CORTEX TUMOR; ADULT; AGED; BLOOD; CARCINOID; CHILD; FACE TUMOR; FEMALE; GASTRINOMA; HEMANGIOFIBROMA; HYPOPHYSIS TUMOR; INSULINOMA; LIPOMA; MALE; MENINGIOMA; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA; PANCREAS TUMOR; PARATHYROID TUMOR; PROLACTINOMA; SECRETION;

CARCINOMA, MEDULLARY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION; PHEOCHROMOCYTOMA; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; ANGIOFIBROMA; CARCINOID TUMOR; CHILD; FACIAL NEOPLASMS; FEMALE; GASTRINOMA; INSULINOMA; LIPOMA; MALE; MENINGIOMA; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; PANCREATIC NEOPLASMS; PARATHYROID NEOPLASMS; PITUITARY NEOPLASMS; PROLACTINOMA; PROTO-ONCOGENE PROTEINS; VASOACTIVE INTESTINAL PEPTIDE; YOUNG ADULT;

EID: 34248191961     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-1-45     Document Type: Review

References (30)

1. Alternative genetic pathways in parathyroid tumorigenesis. F Farnebo S Kytola BT Teh T Dwight FK Wong A Hoog M Elvius WS Wassif NW Thompson LO Farnebo K Sandelin C Larsson, J Clin Endocrinol Metab 1999 84 3775 3780 10.1210/jc.84.10.3775 10523029
2. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. CJ Lips RM Landsvater JW Hoppener RA Geerdink G Blijham JM van Veen AP van Gils MJ de Wit RA Zewald MJ Berends, N Engl J Med 1994 331 828 835 10.1056/NEJM199409293311302 7915822
3. Characterization of the clinical features of five families with hereditary primary cutaneous lichen amyloidosis and multiple endocrine neoplasia type 2. MF Robinson EJ Furst V Nunziata ML Brandi JP Ferrer MJ Martins Bugalho G di Giovanni RJ Smith DT Donovan BR Alford, Henry Ford Hosp Med J 1992 40 249 252 1362415
4. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. LM Mulligan DJ Marsh BG Robinson I Schuffenecker J Zedenius CJ Lips RF Gagel SI Takai WW Noll M Fink, J Intern Med 1995 238 343 346 7595170
5. Multiple endocrine neoplasia type 2: clinical aspects. O Gimm, Front Horm 2001 28 103 130
6. Guidelines for diagnosis and therapy of MEN type 1 and type 2. ML Brandi RF Gagel A Angeli JP Bilezikian P Beck-Peccoz C Bordi B Conte-Devolx A Falchetti RG Gheri A Libroia CJ Lips G Lombardi M Mannelli F Pacini BA Ponder F Raue B Skogseid G Tamburrano RV Thakker NW Thompson P Tomassetti F Tonelli SA Wells Jr SJ Marx, J Clin Endocrinol Metab 2001 86 5658 5671 10.1210/jc.86.12.5658 11739416
7. Poorly differentiated thyroid carcinomas with primordial cell component. A group of aggressive lesions sharing insular, trabecular, and solid patterns. M Papotti F Botto Micca A Favero N Palestini G Bussolati, Am J Surg Pathol 1993 17 291 301 10.1097/00000478-199303000-00010 8434709
8. Multiple endocrine neoplasia syndrome: genetic basis for clinical management. T Carling, Curr Opin Oncol 2005 17 7 12 10.1097/01.cco.0000148567. 29850.31 15608505
9. Natural history of the familial medullary thyroid carcinoma- pheochromocytoma syndrome and the identification of preneoplastic stages by screening studies: a five-year report. RF Gagel KE Melvin AH Tashjian Jr HH Miller ZT Feldman HJ Wolfe RA DeLellis S Cerviskinner S Reichlin, Trans Assoc Am Physicians 1975 88 177 191 1224435
10. Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations. A Miyauchi F Matsuzuka K Hirai T Yokozawa K Kobayashi Y Ito K Nakano K Kuma H Futami K Yamaguchi, World J Surg 2002 26 1023 1028 10.1007/s00268-002-6665-1 12016484
11. Multiple endocrine neoplasia type 2. M Peczkowska A Januszewicz, Fam Cancer 2005 4 25 36 10.1007/s10689-005-0656-y 15883707
12. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. C Eng, N Engl J Med 1996 335 943 951 10.1056/NEJM199609263351307 8782503
13. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. H Dralle O Gimm D Simon K Frank-Raue G Gortz B Niederle RA Wahl B Koch S Walgenbach R Hampel MM Ritter F Spelsberg A Heiss R Hinze W Hoppner, World J Surg 1998 22 744 750 10.1007/s002689900463 9606292
14. Freiburg-Warsaw-Columbus Pheochromocytoma Study Group. "Germ-line mutations in nonsyndromic pheochromocytoma. HP Neumann B Bausch SR McWhinney BU Bender O Gimm G Franke J Schipper J Klisch C Altehoefer K Zerres A Januszewicz C Eng WM Smith R Munk T Manz S Glaesker TW Apel M Treier M Reineke MK Walz C Hoang-Vu M Brauckhoff A Klein-Franke P Klose H Schmidt M Maier-Woelfle M Peczkowska C Szmigielski C Eng, N Engl J Med 2002 346 1459 1466 10.1056/NEJMoa020152 12000816
15. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. H Donis-Keller S Dou D Chi KM Carlson K Toshima TC Lairmore JR Howe JF Moley P Goodfellow SA Wells Jr, Hum Mol Genet 1993 2 851 856 8103403
16. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. LM Mulligan JB Kwok CS Healey MJ Elsdon C Eng E Gardner DR Love SE Mole JK Moore L Papi, Nature 1993 363 458 460 10.1038/363458a0 8099202
17. A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. AM Da Silva RM Maciel MR Da Silva SR Toledo MB De Carvalho JM Cerutti, J Clin Endocrinol Metab 2003 88 5438 5443 10.1210/jc.2003-030997 14602786
18. RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome. MK Punales H Graf JL Gross AL Maia, J Clin Endocrinol Metab 2003 88 2644 2649 10.1210/jc.2002-021422 12788868
19. RET mutation in exons 13 and 14 of FMTC patients. A Bolino I Schuffenencker L Yin M Seri M Silengo T Tocco G Chabrier C Houdent A Murat M Schlumberger J Tourniaire GB Lenoir G Romeo, Oncogene 1995 10 2415 2419 7784092
20. Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. O Gimm DJ Marsh SD Andrew A Frilling PL Dahia LM Mulligan JD Zajac BG Robinson C Eng, J Clin Endocrinol Metab 1997 82 3902 3904 10.1210/jc.82.11.3902 9360560
21. Germline mutation of RET codon 883 in two cases of de novo MEN 2B. DP Smith C Houghton BA Ponder, Oncogene 1997 15 1213 1217 10.1038/sj.onc.1201481 9294615
22. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. S Jing D Wen Y Yu PL Holst Y Luo M Fang R Tamir L Antonio Z Hu R Cupples JC Louis S Hu BW Altrock GM Fox, Cell 1996 85 1113 1124 10.1016/S0092-8674(00)81311-2 8674117
23. The RET receptor: function in development and dysfunction in congenital malformation. S Manie M Santoro A Fusco M Billaud, Trends Genet 2001 17 580 589 10.1016/S0168-9525(01)02420-9 11585664
24. Minireview: RET: normal and abnormal functions. M Santoro RM Melillo F Carlomagno G Vecchio A Fusco, Endocrinology 2004 145 5448 5451 10.1210/en.2004-0922 15331579
25. Dysfunction of the RET receptor in human cancer. M Santoro F Carlomagno RM Melillo A Fusco, Cell Mol Life Sci 2004 61 2954 2964 10.1007/s00018-004-4276- 8 15583857
26. Expression profiles provide insights into early malignant potential and skeletal abnormalities in multiple endocrine neoplasia type 2B syndrome tumors. S Jain MA Watson MK DeBenedetti Y Hiraki JF Moley J Milbrandt, Cancer Res 2004 64 3907 3913 10.1158/0008-5472.CAN-03-3801 15173001
27. Genetic testing in endocrinology: lessons learned from experience with multiple endocrine neoplasia type 2 (MEN2). C Jimenez RF Gagel, Growth Horm IGF Re 2004 14 Suppl A S150 157 10.1016/j.ghir.2004.03.033
28. Surgical treatment of medullary thyroid carcinoma. MS Cohen JF Moley, J Intern Med 2003 253 616 626 10.1046/j.1365-2796.2003.01166.x 12755957
29. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease. C Eng LM Mulligan, Hum Mutat 1997 9 97 109 10.1002/(SICI)1098-1004(1997)9:2<97::AID- HUMU1>3.0.CO;2-M 9067749
30. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. G Cuccuru C Lanzi G Cassinelli G Pratesi M Tortoreto G Petrangolini E Seregni A Martinetti D Laccabue C Zanchi F Zunino, J Natl Cancer Inst 2004 96 1006 1014 15240784